Extrato de Polypodium leucotomos em fotoproteção tópica e oral: dez anos de experiência brasileira / Polypodium leucotomos extract in topical and oral photoprotection: ten years of Brazilian experience

O extrato de Polypodium leucotomos foi inicialmente descrito na literatura internacional há 55 anos, demonstrando ação anti-inflamatória em dermatoses como vitiligo e psoríase. Atualmente, está disponível como fotoprotetor oral e tópico em mais de 26 países e é utilizado na prevenção e no tratamento de dermatoses decorrentes da radiação solar, como erupção polimorfa à luz, melasma, queratoses actínicas, câncer de pele, fotoenvelhecimento, entre outras. No Brasil, o extrato patenteado das folhas de Polypodium leucotomos foi registrado pela Agência Nacional de Vigilância Sanitária (Anvisa) como medicamento em 2012. Decorridos 10 anos de sua introdução no Brasil, sua recomendação por dermatologistas brasileiros está consagrada e será apresentada neste artigo

Polypodium leucotomos extract was first described in the literature 55 years ago, demonstrating anti-inflammatory action in dermatoses such as vitiligo and psoriasis. It is currently available as an oral and topical photoprotection agent in more than 26 countries to prevent and treat dermatoses resulting from solar radiation, such as polymorphous light eruption, melasma, actinic keratoses, skin cancer, and photoaging, among others. In Brazil, ANVISA registered the patented Polypodium leucotomos extract in 2012. After 10 years of its launch, its recommendation by Braziliandermatologists is well established and is presented in this review paper

Avaliação dos índices de qualidade de vida (MELASQoL e DLQI) e do MASI em pacientes com melasma tratadas com Polypodium Leucotomos / Analysis of melasma quality OF life scales (MELASQoL and DLQI) and MASI in Polypodium Leucotomos treated patients

Introdução: Melasma é distúrbio de pigmentação que acomete principalmente mulheres em idade fértil com fototipos elevados. Polypodium leucotomos tem atividade antioxidante, fotoprotetora e imunomodulatória, sendo tratamento adjuvante do melasma. Objetivo: Avaliar a eficácia, em relação à qualidade de vida e à melhora objetiva, do uso de PL no tratamento do melasma. Métodos: Estudo prospectivo e individualizado. Nove voluntárias portadoras de melasma foram submetidas ao tratamento com Polypodium leucotomos durante 45 dias. Escores MELASQoL, DLQI e MASI foram calculados no D0 e no D45. Realizou-se a análise de variância Anova com pós-teste de Tukey para comparação entre D0 e D45 (p < 0,05). Resultados: Todas as pacientes eram do sexo feminino, com média de idade de 37,18 ± 6,78 anos, história familiar de melasma em 55,6%, e fotoexposição desprotegida e uso de estrogênio em 88,9%. Após 45 dias de tratamento com Polypodium leucotomos houve redução significativa do MELASQoL e DLQI (p < 0,05) e melhora do MASI em 55,6% das pacientes. Conclusões: Houve melhora do MASI em 55,6% das pacientes após 45 dias de tratamento. A despeito da discreta melhora no MASI, houve reflexo na melhora dos escores de qualidade de vida (DLQI e MELASQoL).

Introduction: Melasma is a pigmentation disorder that mainly affects women of childbearing age with high phototypes. Polypodium leucotomos has antioxidant, photoprotective and immuno-modulatory activity, and can be considered as an adjunctive treatment for melasma. Objective: To evaluate the efficacy, in relation to quality of life and objective improvement, of the use of Polypodium leucotomos in the treatment of melasma. Methods: Prospective and individualized study. Nine volunteers with melasma were submitted to treatment with Polypodium leucotomos for 45 days. MELASQoL, DLQI and MASI scores were calculated at the beginning (D0) and 45 days after (D45). Analysis of variance ANOVA with Tukey post-test for comparison be-tween D0 and D45 (p <0.05). Results: All patients were females, mean age of 37.18 ± 6.78 years. Family history of melasma in 55.6%; 88.9% with unprotected photoexposure and use of estrogen. After 45 days of treatment with Polypodium leucotomos there was a significant reduction of ME-LASQoL and DLQI (p <0.05) and improvement of MASI in 55.6% of the patients. Conclusions: There was improvement of MASI in 55.6% of patients after 45 days of treatment. In spite of the slight improvement in MASI, there was a reflex in the improvement of quality of life scores (DLQI and MELASQoL).

Antioxidants in dermatology

Abstract The skin cells continuously produce, through cellular respiration, metabolic processes or under external aggressions, highly reactive molecules oxidation products, generally called free radicals. These molecules are immediately neutralized by enzymatic and non-enzymatic systems in a physiological and dynamic balance. In situations where this balance is broken, various cellular structures, such as the cell membrane, nuclear or mitochondrial DNA may suffer structural modifications, triggering or worsening skin diseases. several substances with alleged antioxidant effects has been offered for topical or oral use, but little is known about their safety, possible associations and especially their mechanism of action. The management of topical and oral antioxidants can help dermatologist to intervene in the oxidative processes safely and effectively, since they know the mechanisms, limitations and potential risks of using these molecules as well as the potential benefits of available associations.

Arquitectura y anatomía foliar del complejo Polypodium plesiosorum sensu Moran (Polypodiaceae)

Architecture and leaf anatomy of the Polypodium plesiosorum sensu Moran complex (Polypodiaceae). The Polypodium plesisorum complex is a heterogeneous morphology group. We studied leaf architecture and anatomy of 12 species of this group, in addition to other 23 species of Polypodium (P. dulce, P. polypodioides and P. vulgare complex sensu Moran) and related genera (Goniophlebium, Phlebodium, Pleopeltis, Serpocaulon, Synammia), for comparative purposes. Two homogeneous groups of species were established in P. plesiosorum complex. One of them is recognized based on the type of anastomosis of the veins (Type III): Polypodium conterminans (originally considered in the group of P. dulce with free venation by Moran), P. hispidulum, P. plesiosorum and P. rhodopleuron. The second group with Polypodium arcanum, P. castaneum, P. colpodes, P. eatonii, and P. flagellare were recognized based on the type of anastomosis of the veins (Type IV) and how vascular strands fuse along the petiole-leaf rachis. Characters studied helped to group the remaining species with other groups outside the complex under study. Rev. Biol. Trop. 58 (3): 955-976. Epub 2010 September 01.

El complejo Polypodium plesisorum es un grupo de morfología heterogénea. Se estudió la arquitectura y anatomía foliar de 12 especies que constituyen el complejo de Polypodium plesiosorum reconocidas por Moran, y otras 23 especies de Polypodium (complejos P. dulce, P. polypodioides y P. vulgare sunsu Moran) y géneros relacionados taxonómicamente (Goniophlebium, Phlebodium, Pleopeltis, Serpocaulon, Synammia) con fines comparativos. Dos grupos de especies homogéneas fueron establecidos en el complejo P. plesisorum. Uno de ellos se reconoce por el tipo de anastomosis de las venas (tipo III): Polypodium conterminans (originalmente considerado en el grupo de P. dulce de venación libre según Moran), P. hispidulum, P. plesiosorum y P. rhodopleuron. El segundo grupo formado por Polypodium arcanum, P. castaneum, P. colpodes, P. eatonii y P. flagellare, se reconoce por el tipo de anastomosis de las venas (tipo IV) y la forma en que se fusionan los cordones vasculares a lo largo del eje pecíoloraquis de la hoja. Los caracteres estudiados ayudaron a relacionar las especies restantes con otros grupos fuera del complejo estudiado.